In turnaround, ALX Oncology’s CD47 blocker shows efficacy in gastric cancer trial
03 Oct 2023
Clinical StudyImmunotherapy
Don’t write off CD47 just yet.
ALX Oncology said that 52% of gastric cancer patients who received its anti-CD47 drug evorpacept in combination with a series of other cancer medicines saw their tumors shrink compared to 22% of patients in the control arm that received the other medicines alone.
The striking results in gastric cancer come after the CD47 field has been battered with failures. After Gilead reported that it was stopping a trial for futility, ALX cut two studies in acute myeloid leukemia and its precursor disease, myelodysplastic syndromes, earlier this year due to lack of efficacy.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.